DK1404377T3 - Forbedrede chelatorkonjugater - Google Patents
Forbedrede chelatorkonjugaterInfo
- Publication number
- DK1404377T3 DK1404377T3 DK02745600T DK02745600T DK1404377T3 DK 1404377 T3 DK1404377 T3 DK 1404377T3 DK 02745600 T DK02745600 T DK 02745600T DK 02745600 T DK02745600 T DK 02745600T DK 1404377 T3 DK1404377 T3 DK 1404377T3
- Authority
- DK
- Denmark
- Prior art keywords
- chelator conjugates
- improved
- improved chelator
- radiometal
- conjugates
- Prior art date
Links
- 239000002738 chelating agent Substances 0.000 title abstract 2
- 239000002184 metal Substances 0.000 abstract 1
- 239000012217 radiopharmaceutical Substances 0.000 abstract 1
- 229940121896 radiopharmaceutical Drugs 0.000 abstract 1
- 230000002799 radiopharmaceutical effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0116815.2A GB0116815D0 (en) | 2001-07-10 | 2001-07-10 | Improved chelator conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1404377T3 true DK1404377T3 (da) | 2006-01-30 |
Family
ID=9918227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02745600T DK1404377T3 (da) | 2001-07-10 | 2002-07-10 | Forbedrede chelatorkonjugater |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7597875B2 (da) |
| EP (1) | EP1404377B1 (da) |
| JP (1) | JP5015409B2 (da) |
| KR (1) | KR100892009B1 (da) |
| CN (4) | CN101537190A (da) |
| AT (1) | ATE304866T1 (da) |
| AU (1) | AU2002317317B2 (da) |
| BR (1) | BR0210965A (da) |
| CA (1) | CA2450690C (da) |
| DE (1) | DE60206272T2 (da) |
| DK (1) | DK1404377T3 (da) |
| ES (1) | ES2250671T3 (da) |
| GB (1) | GB0116815D0 (da) |
| HU (1) | HU228850B1 (da) |
| IL (1) | IL159388A0 (da) |
| MX (1) | MXPA04000210A (da) |
| NO (1) | NO334093B1 (da) |
| RU (1) | RU2298012C2 (da) |
| WO (1) | WO2003006070A2 (da) |
| ZA (1) | ZA200400143B (da) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1379885A4 (en) * | 2001-01-05 | 2005-07-06 | Univ Duke | CONTRAST REINFORCING AGENT FOR MAGNETIC RESONANCE IMAGING |
| HU230901B1 (hu) * | 2001-07-10 | 2019-01-28 | Ge Healthcare Limited | Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények |
| NO20030115D0 (no) * | 2003-01-09 | 2003-01-09 | Amersham Health As | Kontrastmiddel |
| US7785566B2 (en) | 2003-11-06 | 2010-08-31 | Ge Healthcare, Inc. | Pharmaceutical compounds |
| GB0416062D0 (en) * | 2004-07-19 | 2004-08-18 | Amersham Plc | Improved N4 chelator conjugates |
| US7431914B2 (en) | 2003-11-24 | 2008-10-07 | Ge Healthcare As | Contrast agent |
| US7763234B2 (en) * | 2004-03-04 | 2010-07-27 | Ge Healthcare As | Pharmaceutical compounds |
| JP5116480B2 (ja) * | 2004-11-22 | 2013-01-09 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 造影剤 |
| GB0427392D0 (en) * | 2004-12-15 | 2005-01-19 | Amersham Plc | Stabilised 99mTc compositions |
| ES2380680T3 (es) * | 2005-06-08 | 2012-05-17 | Ge Healthcare Limited | Procedimiento de uso de monóxido de carbono [11C] en la síntesis de marcaje interno de ésteres marcados con 11C mediante carbonilación fotoinducida de radicales libres sensitizados |
| GB0515974D0 (en) * | 2005-08-03 | 2005-09-07 | Ge Healthcare Ltd | Compounds and imaging methods |
| US8124806B2 (en) | 2006-02-15 | 2012-02-28 | Ge Healthcare As | Contrast agents |
| US7943117B2 (en) * | 2006-06-08 | 2011-05-17 | Atomic Energy Council—Institute of Nuclear Research | Method for testing radiochemical purity of Tc-99m-TRODAT-1 |
| JP2010512310A (ja) * | 2006-12-11 | 2010-04-22 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 放射性標識ペプチド系化合物及びその使用 |
| CN102300866B (zh) | 2008-12-02 | 2015-08-26 | 墨尔本大学 | 作为放射性药物的含氮大环共轭物 |
| GB0922014D0 (en) | 2009-12-17 | 2010-02-03 | Ge Healthcare Ltd | Novel integrin binders |
| ES2804509T3 (es) * | 2010-07-27 | 2021-02-08 | Serac Healthcare Ltd | Composiciones radiofarmacéuticas |
| GB201103696D0 (en) * | 2011-03-04 | 2011-04-20 | Ge Healthcare Ltd | Technetium labelled peptides |
| GB201110767D0 (en) | 2011-06-24 | 2011-08-10 | Ge Healthcare Ltd | Infection imaging |
| US20130195756A1 (en) | 2012-01-31 | 2013-08-01 | General Electric Company | 99mTc IMAGING AGENTS AND METHODS OF USE |
| CN105377287A (zh) * | 2013-02-15 | 2016-03-02 | 托马斯杰弗逊大学 | 用于肿瘤成像的试剂盒 |
| GB201314936D0 (en) | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
| GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
| EP3131585B1 (en) | 2014-03-19 | 2020-07-15 | Universität Zürich | Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy |
| WO2019217571A1 (en) * | 2018-05-08 | 2019-11-14 | University Of Miami | Materials and methods for the delivery of therapeutic nucleic acids to tissues |
| CN112105393A (zh) | 2018-05-16 | 2020-12-18 | 爱默蕾大学 | 苯乙烯基苯并噻唑衍生物及在成像中的用途 |
| CN111548275A (zh) * | 2020-05-27 | 2020-08-18 | 龙曦宁(上海)医药科技有限公司 | 一种2-(氨基甲基)-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1588978A (en) * | 1977-07-19 | 1981-05-07 | Ici Ltd | Coating processes |
| DE3930674A1 (de) * | 1989-09-11 | 1991-03-21 | Diagnostikforschung Inst | Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie |
| US5849261A (en) * | 1991-02-08 | 1998-12-15 | Diatide, Inc. | Radiolabeled vasoactive intestinal peptides for diagnosis and therapy |
| US5808091A (en) * | 1991-10-29 | 1998-09-15 | Bracco International B.V. | Rhenium and technetium complexes containing a hypoxia localizing moiety |
| JP3083157B2 (ja) * | 1993-08-04 | 2000-09-04 | アマーシャム・インターナショナル・ピーエルシー | 酸素欠乏性組織に局在する放射性金属錯体 |
| CA2156605A1 (en) * | 1994-01-12 | 1995-07-20 | Bracco International B.V. | Ligands and metal complexes thereof |
| CA2179990A1 (en) * | 1994-01-12 | 1995-07-20 | Gary Robert Bower | Biological targeting agents |
| HUP0102154A3 (en) * | 1998-05-15 | 2009-01-28 | Ge Healthcare Ltd | Labelled glutamine and lysine analogues |
| US6783711B2 (en) * | 2000-05-23 | 2004-08-31 | Ge Osmonics, Inc. | Process for preparing a sulfonamide polymer matrix |
| JP4009198B2 (ja) | 2001-03-08 | 2007-11-14 | 松下電器産業株式会社 | インクジェット記録用インク、該インクの製造方法、並びに該インクを備えたインクカートリッジ及び記録装置 |
-
2001
- 2001-07-10 GB GBGB0116815.2A patent/GB0116815D0/en not_active Ceased
-
2002
- 2002-07-08 CN CNA200910127855XA patent/CN101537190A/zh active Pending
- 2002-07-08 CN CNA2008102133680A patent/CN101538313A/zh active Pending
- 2002-07-10 JP JP2003511875A patent/JP5015409B2/ja not_active Expired - Lifetime
- 2002-07-10 US US10/483,455 patent/US7597875B2/en not_active Expired - Lifetime
- 2002-07-10 DK DK02745600T patent/DK1404377T3/da active
- 2002-07-10 KR KR1020047000303A patent/KR100892009B1/ko not_active Expired - Fee Related
- 2002-07-10 WO PCT/GB2002/003168 patent/WO2003006070A2/en not_active Ceased
- 2002-07-10 CN CNB028140087A patent/CN100509061C/zh not_active Expired - Fee Related
- 2002-07-10 EP EP02745600A patent/EP1404377B1/en not_active Expired - Lifetime
- 2002-07-10 CA CA002450690A patent/CA2450690C/en not_active Expired - Lifetime
- 2002-07-10 RU RU2003137592/04A patent/RU2298012C2/ru not_active IP Right Cessation
- 2002-07-10 AU AU2002317317A patent/AU2002317317B2/en not_active Ceased
- 2002-07-10 CN CN2009102035216A patent/CN101607913B/zh not_active Expired - Fee Related
- 2002-07-10 HU HU0401265A patent/HU228850B1/hu not_active IP Right Cessation
- 2002-07-10 DE DE60206272T patent/DE60206272T2/de not_active Expired - Lifetime
- 2002-07-10 BR BR0210965-4A patent/BR0210965A/pt active Search and Examination
- 2002-07-10 MX MXPA04000210A patent/MXPA04000210A/es active IP Right Grant
- 2002-07-10 IL IL15938802A patent/IL159388A0/xx unknown
- 2002-07-10 ES ES02745600T patent/ES2250671T3/es not_active Expired - Lifetime
- 2002-07-10 AT AT02745600T patent/ATE304866T1/de active
-
2003
- 2003-12-16 NO NO20035597A patent/NO334093B1/no not_active IP Right Cessation
-
2004
- 2004-01-08 ZA ZA200400143A patent/ZA200400143B/xx unknown
-
2009
- 2009-10-01 US US12/571,508 patent/US8852550B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20035597D0 (no) | Forbedrede chelator-konjugater | |
| MA30153B1 (fr) | Anticorps anti-ox40l et methodes correspondantes | |
| DE60230890D1 (de) | Indolizine als kinaseproteinhemmer | |
| ECSP034600A (es) | Compuestos de lactama | |
| IL181529A (en) | A method for radiofluorination, a compound containing radioactive fluorine and its use in the preparation of a radioactive drug | |
| BRPI0411897A (pt) | pirroldihidroisoquinolinas como inibidores de pde10 | |
| DE50202328D1 (de) | Amidofunktionelle aminopolydiorganosiloxane | |
| BR0307702A (pt) | Formulações de solução contendo anticorpo | |
| MA30042B1 (fr) | Composes calcilytiques | |
| DE60210598D1 (de) | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA | |
| TR200003389T2 (tr) | 2-(2-klorofenil)-3,4-dihidro-2H-pirol türevleri. | |
| DE60124296D1 (de) | Biphenylcarbonsäureamide, die sich als lipidsenker eignen | |
| TW200716605A (en) | 2,6-quinolinyl derivatives, processes for preparing them and their uses | |
| TR199901017A2 (xx) | B�cek ilac� terkibi. | |
| EA200401289A1 (ru) | Новые противоинфекционные соединения, способы их получения и фармацевтические композиции, содержащие эти соединения | |
| DE60322562D1 (de) | Konjugate von tc komplexen und zielgerichtete einheiten und ihre verwendung in nmr-diagnostik | |
| DE60213084D1 (de) | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA | |
| DE60330629D1 (de) | Ether von 2,2,4-Trimethylpentane-1,3-Diolen als Duftstoff | |
| EA200400393A1 (ru) | Антитела против каспазы-8, их получение и применение | |
| NO20021429D0 (no) | 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner | |
| EA200400764A1 (ru) | 1,3-диарилпроп-2-ен-1-оны, композиция на их основе и применение | |
| ITMI20030827A1 (it) | Composizione farmaceutica contenente l'associazione levodopa/carbidopa. | |
| BR0212397A (pt) | Sìntese de glicosìdeos de solano | |
| ES2183543T3 (es) | Derivado de tiocolchicosida, su preparacion y su aplicacion en terapeutica. | |
| HN1999000157A (es) | 1,2,3 tetrahidroquinolinas 2 - sustituidas 4 - amino sustituidas. |